You are not logged in.

The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

Ross, Davi D. M., Grigg, Andrew, Schwarer, Anthony, Arthur, Christopher, Loftus, Kerryn, Mills, Anthony K., Filshie, Robin, Columbus, Ruth, Reynolds, John, Seymour, John, Branford, Susan and Hughes, Timothy 2008, The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early, Blood, vol. 112, no. 11, Abstract # 1102, pp. 1-1.

Attached Files
Name Description MIMEType Size Downloads

Title The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early
Author(s) Ross, Davi D. M.
Grigg, Andrew
Schwarer, Anthony
Arthur, Christopher
Loftus, Kerryn
Mills, Anthony K.
Filshie, Robin
Columbus, Ruth
Reynolds, John
Seymour, John
Branford, Susan
Hughes, Timothy
Journal name Blood
Volume number 112
Issue number 11
Season Abstract # 1102
Start page 1
End page 1
Total pages 1
Publisher American Society of Hematology
Place of publication Washington, D. C.
Publication date 2008-11-16
ISSN 0006-4971
1528-0020
Keyword(s) chronic myeloid leukaemia
patients
imatinib
complete molecular response (CMR)
early relapse
Notes Alternative source title : Blood (ASH Annual Meeting Abstracts); Chronic Myeloid Leukemia - Therapy Poster I presented at American Society of Hematology. Annual Meeting (50th : 2008 : San Francisco, California) held from 6 - 9 Dec. 2008
Language eng
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C2.1 Other contribution to refereed journal
Persistent URL http://hdl.handle.net/10536/DRO/DU:30060085

Document type: Journal Article
Collection: Faculty of Health
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 40 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Thu, 30 Jan 2014, 09:27:55 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.